Pancreatic Cancer Research

ResearcherUniversity of LiverpoolActive in the last 2 years

Julia V. Mayerle

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3666-6459; OpenAlex author ID A5001419911, A5008677072, A5125956155. Sources: OpenAlex.

Their work

Papers
65 (first author 4, last author 11)
Trials
0
Grants
0
Labs led
2
Collaborators
241
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 6 papers · 2017: 3 papers · 2018: 8 papers · 2019: 3 papers · 2020: 8 papers · 2021: 5 papers · 2022: 9 papers · 2023: 3 papers · 2024: 4 papers · 2025: 2 papers · 2026: 2 papers

Papers 50 of 65

  1. STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.01.031↗
  2. Neutrophil-Driven Trogocytosis in Pancreatic Ductal Adenocarcinoma Liver Metastases Restrains Immunosuppressive Macrophage Polarization and Limits Metastatic P… Co-author DOI 10.1053/j.gastro.2026.04.021↗
  3. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  4. Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report. Co-author DOI 10.1159/000545975↗
  5. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Co-author DOI 10.1007/s12094-023-03323-1↗
  6. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades … Co-author DOI 10.1016/j.esmoop.2024.102944↗
  7. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
  8. Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes. Co-author DOI 10.3892/ijo.2024.5614↗
  9. [Pancreatic cancer-screening or surveillance?] Co-author DOI 10.1007/s00117-023-01227-3↗
  10. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
  11. Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pan… Co-author DOI 10.3390/curroncol30060436↗
  12. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  13. Pancreatic cancer: why the cell of origin matters. Co-author DOI 10.1038/s41575-022-00595-w↗
  14. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Last author DOI 10.1053/j.gastro.2022.07.047↗
  15. Nutrient Scavenging From Muscle Cells: A Survival Strategy of Pancreatic Cancer Cells Ends in Cachexia. First author DOI 10.1053/j.gastro.2022.07.069↗
  16. Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkac039↗
  17. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  18. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open rand… Co-author DOI 10.1186/s13014-022-01988-6↗
  19. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review. Co-author DOI 10.1186/s13014-022-02076-5↗
  20. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status. Co-author DOI 10.3390/cancers14215240↗
  21. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenoc… Last author DOI 10.1053/j.gastro.2021.05.055↗
  22. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  23. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  24. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cells10071821↗
  25. Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer. Last author DOI 10.3390/diagnostics11010129↗
  26. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Co-author DOI 10.1007/s00432-019-03061-4↗
  27. [Diabetes and pancreatic cancer - state of the art]. Co-author DOI 10.1007/s15006-020-0428-5↗
  28. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  29. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 st… Co-author DOI 10.1038/s41416-020-01029-7↗
  30. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Last author DOI 10.1093/jncics/pkz060↗
  31. Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13014-020-01624-1↗
  32. FAPα in pancreatic stellate cells upregulated by TGFβ1: a novel insight into pancreatic cancer progress. Last author DOI 10.21037/atm-20-2559↗
  33. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer. First author DOI 10.3390/cancers12041024↗
  34. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  35. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  36. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Co-author DOI 10.1186/s13014-019-1345-6↗
  37. Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer. Co-author DOI 10.1016/j.cca.2017.12.008↗
  38. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Co-author DOI 10.1038/nature25459↗
  39. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  40. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  41. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2018.08.009↗
  42. [Pancreatic Cancer in the Year 2018 - Room for Precision Medicine?] Last author DOI 10.1055/a-0542-4310↗
  43. [Chronic Pancreatitis and Pancreatic Cancer - Tumor Risk and Screening]. Last author DOI 10.1055/s-0043-125407↗
  44. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Co-author DOI 10.1136/gutjnl-2016-312432↗
  45. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  46. Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges. Co-author DOI 10.1152/ajpgi.00138.2017↗
  47. Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model. Co-author DOI 10.18632/oncotarget.15019↗
  48. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. Co-author DOI 10.1016/j.pan.2016.03.005↗
  49. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1038/bjc.2016.277↗
  50. Pancreatic cancer in 2015: Precision medicine in pancreatic cancer--fact or fiction? First author DOI 10.1038/nrgastro.2015.215↗

Closest collaborators

The 25 strongest of 241 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Georg Beyer · 18 shared papers, 2018–2026 · strength 2.33
  2. Markus M. Lerch · 27 shared papers, 2011–2022 · strength 1.52
  3. Ivonne Regel · 9 shared papers, 2018–2026 · strength 1.42
  4. Ujjwal Mukund Mahajan · 14 shared papers, 2015–2024 · strength 1.34
  5. Volker Heinemann · 9 shared papers, 2020–2025 · strength 1.22
  6. Stefan Hubert Boeck · 9 shared papers, 2018–2024 · strength 1.07
  7. Simon Sirtl · 6 shared papers, 2020–2025 · strength 1.00
  8. Frank Ulrich Weiß · 17 shared papers, 2011–2022 · strength 0.95
  9. Steffen Ormanns · 8 shared papers, 2018–2026 · strength 0.92
  10. John P. Neoptolemos · 13 shared papers, 2014–2024 · strength 0.92
  11. Christoph Benedikt Westphalen · 6 shared papers, 2020–2025 · strength 0.86
  12. Marlies Vornhülz · 5 shared papers, 2022–2025 · strength 0.84
  13. Michael Haas · 6 shared papers, 2020–2024 · strength 0.79
  14. Jens Werner · 7 shared papers, 2017–2023 · strength 0.65
  15. Elisabetta Goni · 6 shared papers, 2018–2023 · strength 0.63
  16. Christopher Michael Halloran · 10 shared papers, 2014–2021 · strength 0.62
  17. Klara Dorman · 4 shared papers, 2023–2024 · strength 0.60
  18. William Greenhalf · 9 shared papers, 2014–2021 · strength 0.57
  19. Markus Wolfgang Büchler · 10 shared papers, 2012–2021 · strength 0.56
  20. Jens Thomas Siveke · 4 shared papers, 2021–2024 · strength 0.55
  21. Kirsten Lauber · 4 shared papers, 2019–2026 · strength 0.50
  22. Anke Reinacher‐Schick · 3 shared papers, 2023–2024 · strength 0.47
  23. Jan Goesta D’Haese · 5 shared papers, 2018–2023 · strength 0.47
  24. Daniel H. Palmer · 8 shared papers, 2014–2021 · strength 0.46
  25. Lena Weiss · 3 shared papers, 2023–2024 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.